NVG-2089

Phase 2Small molecule

NNuvig Therapeutics, Inc.

NVG-2089 is one of 49 small molecule programs targeting Immune Thrombocytopenia (ITP). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Thrombocytopenia (ITP)Recruiting

EfficacyRecruiting

Immune Thrombocytopenia (ITP)Phase 2

Recruiting

EfficacyPhase 2

Recruiting

Competition

Competitive Landscape

145 competitors in Efficacy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

4 2

Tivicay

GSK

Phase 3

2 3

Rogaine

Pfizer

Phase 3

1 4

Rayos

RRoxane Laboratories

Phase 3

5 5

Paraplatin

AAvyxa

Phase 3

4 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 7

Alimta

SShawn Eagle

Phase 3

3 8

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 9

Insulin 320

Novo Nordisk

Phase 3

5 10

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Immune Thrombocytopenia (ITP)

NCT07095127

Q2 2028

Phase 2Recruiting

Efficacy

NCT07027111

Clinical

Trials by Indication[1]

Efficacy1 trial

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Recruiting·NNuvig Therapeutics, Inc.·Phase 2·NCT07027111·60 enrolled

Immune Thrombocytopenia (ITP)1 trial

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

Recruiting·NNuvig Therapeutics, Inc.·Phase 2·NCT07095127·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NVG-2089. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NVG-2089 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NVG-2089. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuvig Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNuvig Therapeutics, Inc.

NVG-2089

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Efficacy1 trial

Immune Thrombocytopenia (ITP)1 trial

References

Drug Info

Quick Facts

Related News